Markets & Regulations

Pic:getty/yalcinsonat1

Vertex to acquire ViaCyte, targeting type 1 diabetes

By Rachel Arthur

Vertex Pharmaceuticals will acquire ViaCyte, a privately held biotech focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320m.

© GettyImages/acilo

Kite secures third approved cell therapy indication in Europe

By Jane Byrne

The European Commission (EC) has approved Kite’s CAR T-cell therapy, Yescarta, (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

Pic:getty/hailshadow

Pfizer invests $95m in Valneva

By Rachel Arthur

Pfizer will invest €90.5m ($95m) in French vaccine specialist Valneva, representing 8.1% of Valneva’s share capital. The investment will support the duo’s Lyme disease vaccine partnership.

Pharma industry slams WTO move on TRIPS waiver

Pharma industry slams WTO move on TRIPS waiver

By Jane Byrne

Pharma industry organizations say they are deeply disappointed by the decision taken by World Trade Organization (WTO) at its ministerial conference, MC12, to endorse a TRIPS waiver for COVID-19 vaccines.

Pic:getty/manjurul

GSK gets FDA approval for MMR vaccine Priorix

By Rachel Arthur

The US Food and Drug Administration (FDA) has approved GSK’s Priorix (Measles, Mumps and Rubella Vaccine, Live) for individuals 12 months of age and older.

Pic:getty/andrewbrookes

GSK acquires vaccine company Affinivax

By Rachel Arthur

GSK will acquire Affinivax, a US clinical-stage biopharmaceutical company, for a $2.1bn upfront payment and up to $1.2bn in potential development milestones.